Advertisement

Expression of Concern to: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy

Correction to: Clinical Drug Investigation https://doi.org/10.1007/s40261-019-00862-w

The Editor-in-Chief of Clinical Drug Investigation has become aware that this article [1] contains a number of errors and inconsistencies. In addition, concerns have also been raised regarding the study design and statistical analysis. These concerns are being investigated and an update will be provided once a resolution has been reached. Until then the conclusions of the study should be interpreted with caution.

Gideon Koren and Daniella Gilboa did not agree with this notice; Rachel Katz was informed of the intention to place this notice but did not reply to correspondence regarding this.

Reference

  1. 1.

    Koren G, Gilboa D, Katz R. Fetal safety of dydrogesterone exposure in the first trimester of pregnancy. Clin Drug Investig. 2019. https://doi.org/10.1007/s40261-019-00862-w.

Download references

Author information

Correspondence to Gideon Koren.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Koren, G., Gilboa, D. & Katz, R. Expression of Concern to: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy. Clin Drug Investig (2020). https://doi.org/10.1007/s40261-019-00884-4

Download citation